NCT07072143 An International Study on Pediatric Patients With Rare Tumors.
| NCT ID | NCT07072143 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Azienda Ospedaliera di Padova |
| Condition | Paraganglioma/ Phaeochromocytoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 6,250 participants |
| Start Date | 2025-01-25 |
| Primary Completion | 2049-01-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 6,250 participants in total. It began in 2025-01-25 with a primary completion date of 2049-01-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
Eligibility Criteria
Inclusion Criteria: * Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and/or treated in a participating country/center. * Written informed consent from the patient and/or the parent/legal guardian Exclusion Criteria: * Absence of Written informed consent from the patient and/or the parent/legal guardian
Contact & Investigator
Gianni Bisogno, MD
PRINCIPAL INVESTIGATOR
Azienda Ospedale Università Padova - Italy
Frequently Asked Questions
Who can join the NCT07072143 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 18 Years, studying Paraganglioma/ Phaeochromocytoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07072143 currently recruiting?
Yes, NCT07072143 is actively recruiting participants. Contact the research team at gianni.bisogno@unipd.it for enrollment information.
Where is the NCT07072143 trial being conducted?
This trial is being conducted at Padova, Italy.
Who is sponsoring the NCT07072143 clinical trial?
NCT07072143 is sponsored by Azienda Ospedaliera di Padova. The principal investigator is Gianni Bisogno, MD at Azienda Ospedale Università Padova - Italy. The trial plans to enroll 6,250 participants.